Flavoxate
- Atc Codes:G04BD02
- CAS Codes:3717-88-2#15301-69-6
- PHARMGKB ID:3717-88-2#15301-69-6
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Belgium: Urispas; Denmark: Urispadol; France: Urispas; Germany: Spasuret; Greece: Verispasmin; Ireland: Urispas; Italy: Genurin; Netherlands: Urispas, Uronid; Portugal: Urispas; Slovakia: Genurin; Spain: Uronid; UK: Urispas.
North America
Canada: Flavoxate, Urispas; USA: Flavoxate, Urispas.
Latin America
Argentina: Bladuril; Brazil: Genurin-S; Mexico: Bladuril.
Asia
Japan: Apolakeat, Bladderon, Bolaboran, Flavonate, Flavosert, Gistelink, Harnin, Latobolel, Lollarm, Progut, Ruadan, Sawadaron, Urinaron, Urostate, Urotailon.
Drug combinations
Flavoxate and Propyphenazone
Chemistry
Flavoxate Hydrochloride: C~24~H~25~NO~4~ HCl. Mw: 427.92. (1) 4H-1-Benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-, 2-(1-piperidinyl)ethyl ester, hydrochloride; (2) 2-Piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate hydrochloride. CAS-3717-88-2; CAS-15301-69-6 (flavoxate)(1968).
Pharmacologic Category
Genitourinary Smooth Muscle Relaxants. (ATC-Code: G04BD02).
Mechanism of action
Flavoxate, a derivative of flavone, is a genitourinary antispasmodic. Exerts a direct relaxant effect on smooth muscles via phosphodiesterase inhibition, providing relief to a variety of smooth muscle spasms. Especially useful for treatment of bladder spasticity, whereby it produces increase in urinary capacity.
Therapeutic use
Used as an antispasmodic to provide symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency, and incontinence that may occur in cystitis, prostatitis, urethritis, urethrocystitis, or urethrotrigonitis. Flavoxate not shown to be more effective in treatment of these conditions than antimuscarinic agents.
Pregnancy and lactiation implications
There are no well-controlled studies using flavoxate in pregnant women. Should be used during pregnancy only when clearly needed, and used with caution in nursing women.
Unlabeled use
Contraindications
Hypersensitivity to flavoxate. Pyloric or duodenal obstruction. GI hemorrhage. GI obstruction. Ileus. Achalasia. Obstructive uropathies of lower urinary tract. Benign prostatic hyperplasia.
Warnings and precautions
May cause CNS depression. May cause ocular disturbances, or vertigo. Use with caution in suspected glaucoma.